Takeda Pharmaceutical Company Limited (TAK)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 4
Buy-stop momentum breakout at 19.11, just above the settled 09-17 / 52-week high 19.10 (GTC), with protective stop 18.54 below the 2-session consolidation swing low 18.595 (less 0.06 buffer; 1.90xATR risk, above the 0.5xATR floor) and ATR-scaled targets 19.71 (+2.0xATR) and 20.16 (+3.5xATR); computed R/R 1.05 vs the 1.0 floor. Trend strongly up (price above SMA20/50/200, EMA9/21, VWAP; ADX 32.5 rising; MACD histogram positive), no earnings/dividend events inside the 15-trading-day horizon, liquidity deep ($38.7M 20-day / ~$49.4M recent).
Company overview
Takeda Pharmaceutical Company Limited is a global biopharmaceutical company involved in the discovery, development, manufacturing, and commercialization of pharmaceutical products. It operates across multiple international markets and focuses on therapeutic areas such as gastroenterology, rare diseases, oncology, and neurology. The company collaborates with various partners to enhance its research and development efforts.
Fundamental
fairTakeda's fundamentals are mixed, with strong cash flow and margins offset by leverage and litigation risks.
Takeda screens as undervalued on DCF ($27.84–$33.35/share vs $17.45) with a ~7.94% trailing free-cash-flow yield and strong gross/EBITDA margins. But leverage and coverage are tight (net debt/EBITDA ~3.56x; interest coverage ~1.55x) and SEC filings flag major litigation and patent/pricing risks, keeping overall fundamentals in the “mixed” bucket. FundamentalScore: 3/5.
Sentiment
fairSentiment is mixed, with positive catalysts and legal challenges balancing out.
Mixed, forming setup anchored by the FDA Priority Review acceptance of zasocitinib (announced, 2026-09-14) and the Dr Reddy's Qdenga India distribution deal (announced, 2026-09-18), offset by the confirmed Amitiza antitrust $885M jury loss with class decertification denied (2026-09-15); sentiment delta is determinate but mildly cooling (+0.12 baseline → +0.03 scoring, effectively flat); moderate red-flag cap applied (confirmed material litigation with court-docket confirmation; conflicting bullish/bearish catalyst signals in the same actionable window).
Technical
goodTakeda exhibits a strong uptrend with bullish technical indicators and no overhead resistance.
Strong bullish trend structure across every frame: price 19.05 sits above SMA20 (18.34), SMA50 (17.63), SMA200 (16.93), EMA9 (18.57), EMA21 (18.28) and daily VWAP (19.04), with the MAs stacked bullishly (20>50>200). ADX 32.46 and rising with price above all key MAs confirms an intact, strengthening uptrend rather than a choppy bounce. MACD (0.32/0.30, histogram +0.02) just turned positive on 09-17, and RSI 68.27 confirms strong momentum. Price is at the 52-week high (19.10) with no overhead resistance. Weak signals: RSI 68 / Williams %R -4.35 are near short-term overbought, and the structure-honest stop yields a modest computed R/R of 1.05 — strong but not a perfect 5.
You’re looking at 2026-09-18 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.